{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:10:04Z","timestamp":1700241004789},"reference-count":5,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,5,13]],"date-time":"2003-05-13T00:00:00Z","timestamp":1052784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2003,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This communication describes a patient who developed Schneiderian first\u2010rank symptoms in the course of treatment with fluvoxamine. The patient, a 28\u2010year\u2010old man suffering from panic disorder, developed several first\u2010rank symptoms during fluvoxamine administration. These symptoms abated 1 week after fluvoxamine treatment was discontinued and haloperidol was started. Although haloperidol was discontinued, no further hallucinations or delusions occurred. This finding suggests that fluvoxamine can precipitate Schneiderian first\u2010rank symptoms in some susceptible patients. Copyright \u00a9 2003 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hup.506","type":"journal-article","created":{"date-parts":[[2003,8,12]],"date-time":"2003-08-12T15:25:57Z","timestamp":1060701957000},"page":"477-478","source":"Crossref","is-referenced-by-count":6,"title":["Schneiderian first\u2010rank symptoms associated with fluvoxamine treatment: a case report"],"prefix":"10.1002","volume":"18","author":[{"given":"Nobuhisa","family":"Ueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Terao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,5,13]]},"reference":[{"key":"e_1_2_1_2_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(96)00043-0"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n0107"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920030-00007"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.6.705"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.506","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T16:45:57Z","timestamp":1700239557000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,13]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["10.1002\/hup.506"],"URL":"https:\/\/doi.org\/10.1002\/hup.506","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,13]]}}}